Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on
 
  • Chattem Acquires 5 Leading Johnson & Johnson Brands Rights for Over $400 Million

    January 3rd, 2007 No comments

    Chattem, Inc., a leading marketer and manufacturer of branded consumer products, recently announced the closing of its previously announced agreement to acquire the U.S. rights to five leading consumer and over-the-counter (“OTC”) brands from Johnson & Johnson for $410 million in cash.

    With the acquisition, Chattem’s diverse portfolio of high quality brands has now been expanded to include the following additional brands: KAOPECTATE, an anti-diarrhea product; and BALMEX, a diaper rash product; ACT, an anti-cavity mouthwash/mouth rinse; UNISOM, an OTC sleep aid; CORTIZONE, a hydrocortisone anti-itch product. The acquired brands were divested in connection with the recent acquisition by Johnson & Johnson of Pfizer Inc.’s Consumer Healthcare business and certain regulatory requirements in connection with that acquisition.

    “We are very excited to add these leading brands to the Company’s existing portfolio of quality products,” said Zan Guerry, Chairman and Chief Executive Officer of Chattem. “With the tremendous cooperation of Johnson & Johnson and Pfizer Inc., we have worked very hard over the past several months to help ensure a smooth transition of ownership and remain very excited about the growth potential of these brands.”

    The acquisition was funded in part with the proceeds from a new $300 million term loan provided by Bank of America pursuant to a Fifth Amendment to and restatement of its Credit Agreement, with the remaining funds principally being provided through the use of a portion of the proceeds derived from Chattem’s previously announced sale of 2% Convertible Senior Notes due 2013.

    Chattem, Inc. is a leading marketer and manufacturer of a broad portfolio of branded OTC healthcare products, toiletries and dietary supplements. The Company’s products target niche market segments and are among the market leaders in their respective categories across food, drug and mass merchandisers. The Company’s portfolio of products includes well-recognized brands such as Icy Hot(R), Gold Bond(R), Selsun Blue(R), Garlique(R), Pamprin(R) and BullFrog(R). Chattem conducts a portion of its global business through subsidiaries in the United Kingdom, Ireland and Canada.

    For more information, please visit: www.chattem.com

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 267,436 bad guys.

 

Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round


Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.


Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects


Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding


Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies


Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains


Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster


Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility


 

By using this website you agree with our cookie policy